SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Silsbee who wrote (2365)10/16/1997 7:05:00 PM
From: Henry Niman   of 6136
 
Peter, I was assuming that the failure rate would approach 100% if a patient took PIs with existing drugs. I didn't expect it to hit 100% in 1 or 5 years, but in 20 to 40 years.

Not sure what you mean by the two populations of patients. Resistant strains are somewhat dependent on numbers required. I suspect that most patients have a few copies of resistant virus, but its emergence is dependent one many factors, many of which are host dependent.

The context of the discussion was focused on the failure rates of existing PI's such as Viracept. I did not mean to imply that all or most patients had no hope. My point was that PIs would help, but would not represent anything close to a "cure" for many, if any.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News